{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:50:06Z","timestamp":1793346606859,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Follow-up assessments form the basis for the continuous optimization of therapy and supportive care on an individual level, for confirming treatment efficacy, and for detecting newly emerging or unexpectedly progressive symptoms early enough to permit timely therapeutic intervention. For Pompe disease, evidence based guidelines on which assessments should constitute the minimum standard and which are required in specific situations only, were missing. Therefore, we started the Austrian Pompe Outcome Consensus (APOC) Study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>APOC was a Delphi process with two classical online and a modified third round, implemented September 2023\u2013May 2024, following the AWMF S2k guideline. A five-member interdisciplinary steering committee invited 23 clinical experts, achieving response rates of 69.6% and 100%. A questionnaire was developed via literature scoping and an expert workshop. The importance and recommended frequency of follow-up assessments were rated using AGREE II consensus thresholds, and the classification for recommendation strength of the German Association of the Scientific Medical Societies (AWMF;Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V.).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>34 statements achieved consensus. Strong recommendations included the 6-minute walk test (6MWT), timed tests, Pompe PEDI and other age-appropriate functional tests in children, muscle tests, handheld dynamometry, Fatigue Severity Scale, patient-reported outcome measures (e.g. R-Pact), forced vital capacity (sitting\/supine), morphologic muscle imaging studies, pain and quality of life assessment. Further recommendations included respiratory (MIP\/MEP) and sleep studies (polysomnography), creatine kinase, antibody titers, swallowing studies, liver sonography, hearing tests and speech and speech\/oromotor function, physical therapy and rehabilitation, bone density assessment, and caregiver psychosocial care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The APOC Delphi consensus yields AGREE II\u2013compliant, systematically weighted recommendations delineating essential and optional follow-up assessments for Pompe disease in the context of Austrian healthcare. The applied method enabled a structured and efficient consensus-building process and appears well suited for addressing comparable questions in other rare disease contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04187-0","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:34:59Z","timestamp":1768548899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Austrian Pompe Outcome Consensus (APOC): a national Delphi study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-6961","authenticated-orcid":false,"given":"Florian B.","family":"Lagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Huemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"1","key":"4187_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-017-8686-6","volume":"265","author":"WN L\u00f6scher","year":"2018","unstructured":"L\u00f6scher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, et al. Pompe disease in Austria: clinical, genetic and epidemiological aspects. J Neurol. 2018, Jan;265(1):159\u201364. https:\/\/doi.org\/10.1007\/s00415-017-8686-6.","journal-title":"J Neurol"},{"issue":"8","key":"4187_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.nmd.2015.05.020","volume":"25","author":"B Schoser","year":"2015","unstructured":"Schoser B, Lafor\u00eat P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT; European Pompe Consortium. 208th ENMC International Workshop: Formation of a European network to develop a European data-sharing model and treatment guidelines for Pompe disease. Naarden, The Netherlands, 26\u201328 September 2014. Neuromuscul Disord. 2015 Aug;25(8):684\u201393. https:\/\/doi.org\/10.1016\/j.nmd.2015.05.020.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"4187_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13023-024-03368-7","volume":"19","author":"G Parenti","year":"2024","unstructured":"Parenti G, Fecarotta S, Alagia M, Attaianese F, Verde A, Tarallo A, et al. MetabERN subnetwork for lysosomal disorders. The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II). Orphanet J Rare Dis. 2024, Nov, 1;19(1):358. https:\/\/doi.org\/10.1186\/s13023-024-03368-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4187_CR4","doi-asserted-by":"publisher","first-page":"e16383","DOI":"10.1111\/ene.16383","volume":"31","author":"B Schoser","year":"2024","unstructured":"Schoser B, van der Beek NAME, Broomfield A, Brusse E, Diaz-Manera J, Hahn A, et al. European Pompe Consortium. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur J Neurol. 2024, Sep;31(9):e16383. https:\/\/doi.org\/10.1111\/ene.16383.","journal-title":"Eur J Neurol"},{"issue":"6","key":"4187_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/ene.13323","volume":"24","author":"van der Ploeg At","year":"2017","unstructured":"van der Ploeg At, Kruijshaar ME, Toscano A, Lafor\u00eat, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017, Jun;24(6):1325\u201334. https:\/\/doi.org\/10.1111\/ene.13323.","journal-title":"Eur J Neurol"},{"issue":"1","key":"4187_CR6","doi-asserted-by":"publisher","first-page":"e1000393","DOI":"10.1371\/journal.pmed.1000393","volume":"8","author":"IP Sinha","year":"2011","unstructured":"Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011, Jan, 25;8(1):e1000393. https:\/\/doi.org\/10.1371\/journal.pmed.1000393.","journal-title":"PLoS Med"},{"key":"4187_CR7","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-St\u00e4ndige Kommission Leitlinien. AWMF-Regelwerk \u201eLeitlinien\u201c. Auflage 2.1 2023. Verf\u00fcgbar: https:\/\/www.awmf.org\/regelwerk\/."},{"issue":"8","key":"4187_CR8","doi-asserted-by":"publisher","first-page":"e0280010","DOI":"10.1371\/journal.pone.0280010","volume":"19","author":"M Niederberger","year":"2024","unstructured":"Niederberger M, Schifano J, Deckert S, Hirt J, Homberg A, K\u00f6berich S, et al. Delphi studies in social and health sciences-recommendations for an interdisciplinary standardized reporting (DELPHISTAR). PLoS One. 2024, Aug, 26;19(8):e0280010. https:\/\/doi.org\/10.1371\/journal.pone.0280010.","journal-title":"PLoS One"},{"issue":"18","key":"4187_CR9","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/cmaj.090449","volume":"182","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Agree ii: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010, Dec, 14;182(18):E839\u201342.","journal-title":"CMAJ"},{"issue":"7","key":"4187_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s12098-023-04575-z","volume":"90","author":"MJL Efficiency","year":"2023","unstructured":"Efficiency MJL. Economy and excellence: experimental exploration of evidence-based guideline development in resource-constrained settings. Indian J Pediatr. 2023, Jul;90(7):700\u201307. https:\/\/doi.org\/10.1007\/s12098-023-04575-z.","journal-title":"Indian J Pediatr"},{"key":"4187_CR11","doi-asserted-by":"publisher","unstructured":"Coulter I, Elfenbaum P, Jain S, et al. SEaRCH\u2122 expert panel process: streamlining the link between evidence and practice. BMC Res Notes. 2016;9:16. https:\/\/doi.org\/10.1186\/s13104-015-1802-8.","DOI":"10.1186\/s13104-015-1802-8"},{"key":"4187_CR12","doi-asserted-by":"publisher","unstructured":"Normahani P, Sounderajah V, Harrop-Griffiths W, Chukwuemeka A, Peters NS, Standfield NJ, et al. Achieving good-quality consent: review of literature, case law and guidance. BJS Open. 2020;4(5):757\u2013763. https:\/\/doi.org\/10.1002\/bjs5.50306.","DOI":"10.1002\/bjs5.50306"},{"issue":"2","key":"4187_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2016, Mar;39(2):253\u201360. https:\/\/doi.org\/10.1007\/s10545-015-9889-6.","journal-title":"J Inherit Metab Dis"},{"issue":"14","key":"4187_CR14","doi-asserted-by":"publisher","first-page":"1195302","DOI":"10.3389\/fneur.2023.1195302","volume":"29","author":"CI Angelini","year":"2023","unstructured":"Angelini CI, Ansevin C, Siciliano G. The role of sleep in neuromuscular disorders. Front Neurol. 2023, Jun;29(14):1195302. https:\/\/doi.org\/10.3389\/fneur.2023.1195302.","journal-title":"Front Neurol"},{"issue":"4","key":"4187_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jimd.12606","volume":"46","author":"A Lika","year":"2023","unstructured":"Lika A, Andrinopoulou ER, van der Beek NAME, Rizopoulos D, van der Ploeg AT, Kruijshaar ME. Association between changes in pulmonary function and in patient-reported outcomes during enzyme therapy of adult patients with late-onset Pompe disease. J Inherit Metab Dis. 2023, Jul;46(4):595\u2013604. https:\/\/doi.org\/10.1002\/jimd.12606.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 2","key":"4187_CR16","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.21037\/jtd-cus-2020-007","volume":"12","author":"NM Shah","year":"2020","unstructured":"Shah NM, Sharma L, Ganeshamoorthy S, Kaltsakas G. Respiratory failure and sleep-disordered breathing in late-onset Pompe disease: a narrative review. J Thorac Dis. 2020, Oct;12(Suppl 2):S235\u201347. https:\/\/doi.org\/10.21037\/jtd-cus-2020-007.","journal-title":"J Thorac Dis"},{"issue":"8","key":"4187_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nmd.2019.06.011","volume":"29","author":"J Spiesshoefer","year":"2019","unstructured":"Spiesshoefer J, Henke C, Kabitz HJ, Brix T, G\u00f6rlich D, Herkenrath S, et al. The nature of respiratory muscle weakness in patients with late-onset Pompe disease. Neuromuscul Disord. 2019, Aug;29(8):618\u201327. https:\/\/doi.org\/10.1016\/j.nmd.2019.06.011.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"4187_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.nmd.2020.06.009","volume":"30","author":"S Wenninger","year":"2020","unstructured":"Wenninger S, Stahl K, Wirner C, Einvag K, Thiele S, Walter MC, et al. Utility of maximum inspiratory and expiratory pressures as a screening method for respiratory insufficiency in slowly progressive neuromuscular disorders. Neuromuscul Disord. 2020, Aug;30(8):640\u201348. https:\/\/doi.org\/10.1016\/j.nmd.2020.06.009.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"4187_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","volume":"85","author":"Y An","year":"2005","unstructured":"An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corz D, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab. 2005, Aug;85(4):247\u201354. https:\/\/doi.org\/10.1016\/j.ymgme.2005.03.010.","journal-title":"Mol Genet Metab"},{"issue":"23","key":"4187_CR20","doi-asserted-by":"publisher","first-page":"100581","DOI":"10.1016\/j.ymgmr.2020.100581","volume":"1","author":"M Piraud","year":"2020","unstructured":"Piraud M, Pettazzoni M, de Antonio M, Vianey-Saban C, Froissart R, Chabrol B, et al. Urine glucose tetrasaccharide: a good biomarker for glycogenoses type II and III? A study of the French cohort. Mol Genet Metab Rep. 2020, May;1(23):100581. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100581.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4187_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajmg.c.31320","volume":"160C","author":"SP Young","year":"2012","unstructured":"Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet C Semin Med Genet. 2012, Feb 15;160C(1):50\u201358. https:\/\/doi.org\/10.1002\/ajmg.c.31320.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"13","key":"4187_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2019.05.27","volume":"7","author":"AK Desai","year":"2019","unstructured":"Desai AK, Li C, Rosenberg AS, Kishnani PS. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med. 2019, Jul;7(13):285. https:\/\/doi.org\/10.21037\/atm.2019.05.27.","journal-title":"Ann Transl Med"},{"key":"4187_CR23","doi-asserted-by":"publisher","first-page":"15034","DOI":"10.1038\/mtm.2015.34","volume":"3","author":"E Masat","year":"2016","unstructured":"Masat E, Lafor\u00eat P, De Antonio M, Corre G, Perniconi B, Taouagh N, et al. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Mol Ther Methods Clin Dev. 2016, Jan;3:15034. https:\/\/doi.org\/10.1038\/mtm.2015.34.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"36","key":"4187_CR24","doi-asserted-by":"publisher","first-page":"100981","DOI":"10.1016\/j.ymgmr.2023.100981","volume":"13","author":"KH Kim","year":"2023","unstructured":"Kim KH, Desai AK, Vucko ER, Boggs T, Kishnani PS, Burton BK. Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy. Mol Genet Metab Rep. 2023, Jun;13(36):100981. https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100981.","journal-title":"Mol Genet Metab Rep"},{"issue":"12","key":"4187_CR25","doi-asserted-by":"publisher","first-page":"675781","DOI":"10.3389\/fneur.2021.675781","volume":"8","author":"A Alonso-Jim\u00e9nez","year":"2021","unstructured":"Alonso-Jim\u00e9nez A, Nu\u00f1ez-Peralta C, Montesinos P, Alonso-P\u00e9rez J, Garc\u00eda C, Montiel E, et al. Different approaches to analyze muscle fat replacement with Dixon MRI in Pompe disease. Front Neurol. 2021, Jul;8(12):675781. https:\/\/doi.org\/10.3389\/fneur.2021.675781.","journal-title":"Front Neurol"},{"issue":"1","key":"4187_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nmd.2021.11.001","volume":"32","author":"L Harlaar","year":"2022","unstructured":"Harlaar L, Ciet P, van Tulder G, Brusse E, Timmermans RGM, Janssen WGM, et al. Diaphragmatic dysfunction in neuromuscular disease, an MRI study. Neuromuscul Disord. 2022, Jan;32(1):15\u201324. https:\/\/doi.org\/10.1016\/j.nmd.2021.11.001.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"4187_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/jcsm.12555","volume":"11","author":"C Nu\u00f1ez-Peralta","year":"2020","unstructured":"Nu\u00f1ez-Peralta C, Alonso-P\u00e9rez J, Llauger J, Segovia S, Montesinos P, Belmonte I, et al. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles. J Cachexia Sarcopenia Muscle. 2020, Aug;11(4):1032\u201346. https:\/\/doi.org\/10.1002\/jcsm.12555.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4187_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejpn.2022.12.002","volume":"42","author":"YH Chiu","year":"2023","unstructured":"Chiu YH, Liao CL, Chien YH, Wu CH, \u00d6z\u00e7akar L. Sonographic evaluations of the skeletal muscles in patients with Pompe disease. Eur J Paediatr Neurol. 2023, Jan;42:22\u201327. https:\/\/doi.org\/10.1016\/j.ejpn.2022.12.002.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"4187_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.numecd.2021.01.002","volume":"31","author":"F Carubbi","year":"2021","unstructured":"Carubbi F, Barbato A, Burlina AB, Francini F, Mignani R, Pegoraro E, et al. Nutrition in adult patients with selected lysosomal storage diseases. Nutr Metab Cardiovasc Dis. 2021, Mar;31(3):253\u201360. https:\/\/doi.org\/10.1016\/j.numecd.2021.01.002.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"4187_CR30","doi-asserted-by":"publisher","first-page":"1178348","DOI":"10.3389\/fnut.2023.1178348","volume":"11","author":"E Massimino","year":"2023","unstructured":"Massimino E, Amoroso AP, Lupoli R, Rossi A, Capaldo B. Nutritional management of glycogen storage disease type iii: a case report and a critical appraisal of the literature. Front Nutr. 2023, May;11(10):1178348. https:\/\/doi.org\/10.3389\/fnut.2023.1178348.","journal-title":"Front Nutr"},{"issue":"1\u20132","key":"4187_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2022.06.001","volume":"137","author":"MI Nilsson","year":"2022","unstructured":"Nilsson MI, Crozier M, Di Carlo A, Xhuti D, Manta K, Roik LJ, et al. Nutritional co-therapy with 1, 3-butanediol and multi-ingredient antioxidants enhances autophagic clearance in Pompe disease. Mol Genet Metab. 2022, Sep-Oct;137(1\u20132):228\u201340. https:\/\/doi.org\/10.1016\/j.ymgme.2022.06.001.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4187_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017, Apr;15(2):127\u201337. https:\/\/doi.org\/10.1007\/s40258-017-0310-5.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"4187_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13023-024-03368-7","volume":"19","author":"MI Truninger","year":"2024","unstructured":"Truninger MI, Werner H, Landolt MA, Hahn A, Hennermann JB, Lagler FB, et al. Living with Pompe disease: results from a qualitative interview study with children and adolescents and their caregivers. Orphanet J Rare Dis. 2024, Sep, 28;19(1):358. https:\/\/doi.org\/10.1186\/s13023-024-03368-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4187_CR34","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/jimd.12777","volume":"47","author":"MI Truninger","year":"2024","unstructured":"Truninger MI, Werner H, Landolt MA, Hahn A, Hennermann JB, Lagler FB, et al. The PompeQoL questionnaire: development and validation of a new measure for children and adolescents with Pompe disease. J Inherit Metab Dis. 2024, Nov;47(6):1348\u201362. https:\/\/doi.org\/10.1002\/jimd.12777.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"4187_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13023-020-01469-7","volume":"15","author":"M Yuan","year":"2020","unstructured":"Yuan M, Andrinopoulou ER, Kruijshaar ME, Lika A, Harlaar L, van der Ploeg AT, et al. Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study. Orphanet J Rare Dis. 2020, Sep, 3;15(1):232. https:\/\/doi.org\/10.1186\/s13023-020-01469-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4187_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13023-022-02545-w","volume":"17","author":"Z Al-Hassnan","year":"2022","unstructured":"Al-Hassnan Z, Hashmi NA, Makhseed N, Omran TB, Al Jasmi F, Teneiji AA. Expert group consensus on early diagnosis and management of infantile-onset Pompe disease in the gulf region. Orphanet J Rare Dis. 2022, Oct, 27;17(1):388. https:\/\/doi.org\/10.1186\/s13023-022-02545-w.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4187_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/a-1110-7335","volume":"232","author":"A Hahn","year":"2020","unstructured":"Hahn A, Hennermann JB, Huemer M, Kampmann C, Marquardt T, Mengel E, et al. Diagnosis and care of infants and children with Pompe disease. Klin Padiatr. 2020, Feb, 18;232(1):35\u201344. https:\/\/doi.org\/10.1055\/a-1110-7335.","journal-title":"Klin Padiatr"},{"issue":"3","key":"4187_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nmd.2022.01.001","volume":"32","author":"M Winkler","year":"2022","unstructured":"Winkler M, von Landenberg C, Kuchenbecker K, Reimann J, Kornblum C. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease. Neuromuscul Disord. 2022, Mar;32(3):195\u2013205. https:\/\/doi.org\/10.1016\/j.nmd.2022.01.001.","journal-title":"Neuromuscul Disord"},{"key":"4187_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pediatrneurol.2025.08.003","volume":"172","author":"M Boueri","year":"2025","unstructured":"Boueri M, Paltzer A, Huggins E, Linebaugh E, Zvejnieks D, Doxey J, et al. Navigating the emotional and practical challenges of newborn screening for late-onset Pompe disease: insights from parental perspectives. Pediatr Neurol. 2025, Nov;172:94\u2013100. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2025.08.003. Epub 2025 Aug 12. PMID: 40912068.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"4187_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13023-023-02924-x","volume":"18","author":"G Ismailova","year":"2023","unstructured":"Ismailova G, Wagenmakers MAEM, Brusse E, van der Ploeg AT, Favejee MM, van der Beek NAME, et al. Long-term benefits of physical activity in adult patients with late onset Pompe disease: a retrospective cohort study with 10 years of follow-up. Orphanet J Rare Dis. 2023, Oct, 11;18(1):319. https:\/\/doi.org\/10.1186\/s13023-023-02924-x. PMID: 37821981; PMCID: PMC10566098.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4187_CR41","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.4081\/ni.2019.7983","volume":"11","author":"B Corrado","year":"2019","unstructured":"Corrado B, Ciardi G, Iammarrone CS. Rehabilitation management of Pompe disease, from childhood through adulthood: a systematic review of the literature. Neurol Int. 2019, Jun, 18;11(2):7983. https:\/\/doi.org\/10.4081\/ni.2019.7983.","journal-title":"Neurol Int"},{"issue":"1","key":"4187_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/PRM-190601","volume":"13","author":"KD Crisp","year":"2020","unstructured":"Crisp KD, Case LE, Kravitz RM, Kishnani PS, Jones HN. Training, detraining, and retraining: two 12-week respiratory muscle training regimens in a child with infantile-onset Pompe disease. J Pediatr Rehabil Med. 2020;13(1):71\u201380. https:\/\/doi.org\/10.3233\/PRM-190601.","journal-title":"J Pediatr Rehabil Med"},{"issue":"1\u20132","key":"4187_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymgme.2012.07.014","volume":"107","author":"MM Favejee","year":"2012","unstructured":"Favejee MM, Huisstede BM, Bussmann JB, Kruijshaar ME, van der Ploeg AT. Physiotherapy management in late-onset Pompe disease: clinical practice in 88 patients. Mol Genet Metab. 2012, Sep;107(1\u20132):111\u201315. https:\/\/doi.org\/10.1016\/j.ymgme.2012.07.014.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4187_CR44","first-page":"241","volume":"37","author":"G Iolascon","year":"2018","unstructured":"Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S, et al. The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence. Acta Myol. 2018, Dec, 1;37(4):241\u201351.","journal-title":"Acta Myol"},{"issue":"4","key":"4187_CR45","first-page":"215","volume":"38","author":"AM Sheikh","year":"2019","unstructured":"Sheikh AM, Vissing J. Exercise therapy for muscle and lower motor neuron diseases. Acta Myol. 2019, Dec, 1;38(4):215\u201332.","journal-title":"Acta Myol"},{"issue":"10","key":"4187_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-015-0303-0","volume":"19","author":"van den Berg LE","year":"2015","unstructured":"van den Berg LE, Favejee MM, Wens SC, Kruijshaar ME, Praet SF, Reuser AJ, et al. Safety and efficacy of exercise training in adults with Pompe disease: evaluation of endurance, muscle strength and core stability before and after a 12-week training program. Orphanet J Rare Dis. 2015, Jul;19(10):87. https:\/\/doi.org\/10.1186\/s13023-015-0303-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4187_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00415-018-9112-4","volume":"266","author":"S Wenninger","year":"2019","unstructured":"Wenninger S, Greckl E, Baba\u010di\u0107 H, Stahl K, Schoser B. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study. J Neurol. 2019, Jan;266(1):133\u201347. https:\/\/doi.org\/10.1007\/s00415-018-9112-4.","journal-title":"J Neurol"},{"issue":"9","key":"4187_CR48","doi-asserted-by":"publisher","first-page":"e966","DOI":"10.1212\/WNL.0000000000207547","volume":"101","author":"C Lefeuvre","year":"2024","unstructured":"Lefeuvre C, De Antonio M, Bouhour F, Tard C, Salort-Campana E, Lagrange E, et al. For Pompe study group. Characteristics of patients with late-onset Pompe disease in France: insights from the French Pompe registry in 2022. Neurology. 2024, 2023 Aug, 29;101(9):e966\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000207547. Epub 2023 Jul 7. Erratum in: Neurology. 2024 Aug 13; 103(3):e209578.10.1212\/WNL.0000000000209578. PMID: 37419682; PMCID: PMC10501092.","journal-title":"Neurology"},{"key":"4187_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nmd.2023.10.001","volume":"34","author":"RJ Martinez-Marin","year":"2024","unstructured":"Martinez-Marin RJ, Reyes-Leiva D, Nascimento A, Muelas N, Dominguez-Gonz\u00e1lez C, Paradas C, et al. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry. Neuromuscul Disord. 2024, Jan;34:1\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2023.10.001. Epub 2023 Nov 13. PMID: 38087756.","journal-title":"Neuromuscul Disord"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04187-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:44:10Z","timestamp":1770831850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04187-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4187"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04187-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The study was financially and logistically supported by Sanofi-Aventis GmbH (Vienna, Austria). Sanofi had no influence on study design, data collection, analysis, interpretation, or reporting. Funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}